Dementia Associated With Alzheimer'S Disease - Pipeline Insight, 2026

This “Dementia Associated With Alzheimer’s Disease - Pipeline Insight, 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Dementia Associated With Alzheimer’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Dementia Associated With Alzheimer’s Disease: Understanding

Dementia Associated With Alzheimer’s Disease: Overview

Dementia is a general term used to describe a significant decline in cognitive ability that interferes with a person's activities of daily living. Alzheimer disease (AD) is the most prevalent type of dementia, accounting for at least two-thirds of cases in individuals aged 65 and older. AD is a neurodegenerative condition with insidious onset and progressive impairment of behavioral and cognitive functions. These functions include memory, comprehension, language, attention, reasoning, and judgment. While AD does not directly cause death, it substantially raises vulnerability to other complications, which can eventually lead to a person's death.

Dementia associated with Alzheimer's disease (AD) arises primarily from progressive neurodegeneration driven by the accumulation of amyloid-beta plaques outside neurons and tau protein tangles inside them, which disrupt cell communication, impair nutrient transport, and trigger widespread neuronal death, particularly in memory-related regions like the hippocampus and cortex. Genetic factors play a key role, with rare mutations in APP, PSEN1, and PSEN2 genes causing early-onset familial AD (less than 5% of cases), while the APOE ε4 allele significantly elevates risk for late-onset sporadic AD, the most common form after age 65.

Diagnosing dementia associated with Alzheimer's disease typically involves a comprehensive assessment that includes medical history, cognitive testing, physical and neurological exams, and, if necessary, brain imaging. Doctors first rule out other potential causes of memory loss and cognitive decline, such as vitamin deficiencies or thyroid problems. Cognitive tests assess memory, problem-solving skills, and language abilities to detect patterns consistent with Alzheimer’s. Neuroimaging, like MRI or CT scans, may be used to identify brain changes such as atrophy in specific areas. Advanced tests, including PET scans or cerebrospinal fluid analysis, can detect biomarkers associated with Alzheimer’s, providing more definitive evidence.

There is currently no cure for dementia associated with Alzheimer's disease, the treatment relies on symptomatic therapies, as no cure exists, with two main FDA-approved drug categories: cholinesterase inhibitors and partial N-methyl D-aspartate (NMDA) antagonists. Cholinesterase inhibitors increase acetylcholine levels to support nerve cell communication, while partial NMDA antagonists like memantine block excessive glutamate activity to prevent neuronal damage in moderate to severe cases.

"Dementia Associated With Alzheimer’s Disease- Pipeline Insight, 2026" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dementia Associated With Alzheimer’s Disease pipeline landscape is provided which includes the disease overview and Dementia Associated With Alzheimer’s Disease treatment guidelines. The assessment part of the report embraces, in depth Dementia Associated With Alzheimer’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dementia Associated With Alzheimer’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Dementia Associated With Alzheimer’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Dementia Associated With Alzheimer’s Disease.

Dementia Associated With Alzheimer’s Disease Emerging Drugs Chapters

This segment of the Dementia Associated With Alzheimer’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dementia Associated With Alzheimer’s Disease Emerging Drugs

• Trontinemab: F. Hoffmann-La Roche Ltd.

Trontinemab is an investigational Brainshuttle™ bispecific 2+1 amyloid-beta antibody specifically engineered for enhanced access to the brain to enable rapid reduction of amyloid in people with Alzheimer's disease. Trontinemab is designed for the efficient transport across the blood-brain barrier to target aggregated forms of amyloid beta and remove amyloid plaques in the brain. The uniqueness of trontinemab is based on Roche's proprietary Brainshuttle technology combining an amyloid beta-binding monoclonal antibody with a transferring receptor (TfR1) shuttle module. As a result, high central nervous system (CNS) exposure of trontinemab may be achieved at low doses, leading to a rapid and deep amyloid clearance. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Dementia Associated With Alzheimer’s Disease.

• E2814: Eisai Co., Ltd.

E2814 is an investigational anti-MTBR tau antibody designed to target the MTBR of tau, an area critical for the formation of pathogenic tau species. These MTBR-containing tau fragments are believed to act as “tau seeds” that drive the spread of neurofibrillary pathology across synaptically connected brain regions. By selectively binding to this region, E2814 aims to neutralize these seeding-competent tau species, thereby interrupting the cell-to-cell transmission of tau aggregates and potentially slowing disease progression in Alzheimer’s disease. Currently, the drug is being evaluated in the Phase II/III stage of its development for the treatment of Dementia Associated With Alzheimer’s Disease.

• MK-1167: Merck & Co. / Neuphoria Therapeutics, Inc.

MK-1167 acts as a positive allosteric modulator of the α7 nicotinic acetylcholine receptor, which plays a key role in memory and learning. By enhancing cholinergic signaling in the brain, the drug is intended to improve cognitive function. MK-1167 represents a novel approach targeting neurotransmitter pathways involved in cognition. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Dementia Associated With Alzheimer’s Disease.

• ONO-2020: ONO PHARMACEUTICAL CO., LTD.

ONO-2020 is an investigational, orally administered small-molecule drug. This drug act as an epigenetic modulator, influencing gene expression in the central nervous system without altering the underlying DNA sequence. By targeting pathways involved in neuronal signaling, synaptic plasticity, and inflammation, the drug aims to restore functional balance in brain circuits that are disrupted in Alzheimer’s disease. It acts as an epigenetic regulator, aiming to modify gene expression to potentially slow or halt Alzheimer’s progression, rather than just managing symptoms. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Dementia Associated With Alzheimer’s Disease.

• ARO-MAPT: Arrowhead Pharmaceuticals, Inc.

ARO-MAPT is designed to silence CNS expression of the microtubule associated protein tau (MAPT) gene, which encodes the tau protein. Aggregation of the toxic tau protein is believed to be a key driver in multiple tauopathies, including Alzheimer’s disease. By preventing or potentially reversing tau protein accumulation in subjects with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia, ARO-MAPT has potential to prevent or slow disease progression. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Dementia Associated With Alzheimer’s Disease.

• COYA 302: Coya Therapeutics, Inc/Dr. Reddy’s Laboratories Ltd.

COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. This drug is a proprietary combination of COYA 301 (Coya’s proprietary LD IL-2) and CTLA4-Ig for subcutaneous administration with a unique dual mechanism of action that is now being developed for the treatment of Alzheimer’s disease. Its multi-targeted approach enhances the number and anti-inflammatory function of Tregs and simultaneously lowers the expression of activated microglia and the secretion of pro-inflammatory mediators. Currently, the drug is being evaluated in the preclinical stage of its development for the treatment of Dementia Associated with Alzheimer’s disease.

Further product details are provided in the report……..

Dementia Associated With Alzheimer’s Disease: Therapeutic Assessment

This segment of the report provides insights about the different Dementia Associated With Alzheimer’s Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Dementia Associated With Alzheimer’s Disease

There are approx. 80+ key companies which are developing the therapies Dementia Associated With Alzheimer’s Disease. The companies which have their Dementia Associated With Alzheimer’s Disease drug candidates in the most advanced stage, i.e. Phase III include, F. Hoffmann-La Roche Ltd., and others.

Phases

The report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Dementia Associated With Alzheimer’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dementia Associated With Alzheimer ’s disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dementia Associated With Alzheimer’s Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dementia Associated With Alzheimer’s Disease drugs.

Dementia Associated With Alzheimer’s Disease Report Insights

• Dementia Associated With Alzheimer’s Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dementia Associated With Alzheimer’s Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Dementia Associated With Alzheimer’s Disease drugs?
• How many Dementia Associated With Alzheimer’s Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dementia Associated With Alzheimer’s Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dementia Associated With Alzheimer’s Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dementia Associated With Alzheimer’s Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• F. Hoffmann-La Roche Ltd.
• Eisai Co., Ltd.
• Merck & Co.
• Neuphoria Therapeutics, Inc.
• ONO PHARMACEUTICAL CO., LTD.
• Arrowhead Pharmaceuticals, Inc.
• Coya Therapeutics, Inc.
• Dr. Reddy’s Laboratories Ltd.
• Cerecin Inc.
• Novartis AG
• Aribio
• Suven Life Sciences Limited
• Annovis Bio, Inc.
• Eli Lilly and Company
• Alnylam Pharmaceuticals, Inc.
• Alector, Inc.
• Actinogen Medical
• Shanghai Auzone Biological Technology Co., Ltd.
• AB Science
• T3D Therapeutics, Inc.
• Cognition Therapeutics
• Lighthouse Pharmaceuticals, Inc.
• Spinogenix, Inc.
• EXCIVA GmbH
• NSC-Therapeutics

Key Products

• Trontinemab
• E2814
• MK-1167
• ONO-2020
• ARO-MAPT
• COYA 302
• Tricaprilin
• VHB937
• AR1001
• Masupirdine
• Buntanetap
• Mevidalen
• ALN-5288
• AL101
• Xanamem (Emestedastat)
• TTYP01
• Masitinib
• T3D-959
• Zervimesine
• LHP588
• SPG302
• EXV-802
• NSC001

This product will be delivered within 2-4 business days.